Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0043-1768567
What Does an Adult Hemato-Oncology Physician Expect from a Hematopathologist?
Funding None.![](https://www.thieme-connect.de/media/10.1055-s-00050348/202305/lookinside/thumbnails/10-1055-s-0043-1768567_222501009-1.jpg)
Abstract
Recent advances in the field of hemato-oncology have significantly improved outcomes for patients. However, these changes have also increased the complexity of investigations required at the time of diagnosis and during the follow-up of these patients. Close interaction and exchange of information between the pathologist and the clinician is important for sucessful management of patients. This article briefly discusses the advances in the field and the impact of these changes on the management of patients. A clinician's perspective of what is required from a hematopathologist while managing patients in the current era is presented. An attempt is made to classify the requirements as to what is expected in ideal as well as in resource-limited settings.
Publication History
Article published online:
04 November 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT. Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol 2014; 32 (03) 163-168
- 2 Kantarjian H. Acute myeloid leukemia: major progress over four decades and glimpses into the future. Am J Hematol 2016; 91 (01) 131-145
- 3 Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol 2020; 13 (01) 70
- 4 Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 2020; 95 (05) 548-567
- 5 O'Brien SG, Guilhot F, Larson RA. et al; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348 (11) 994-1004
- 6 Huang SJ, Gerrie AS, Young S. et al. Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada. Leuk Res 2020; 91: 106335
- 7 Coiffier B, Lepage E, Briere J. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346 (04) 235-242
- 8 Mathews V, George B, Chendamarai E. et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 2010; 28 (24) 3866-3871
- 9 Brüggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Blood Adv 2017; 1 (25) 2456-2466
- 10 Gökbuget N, Dombret H, Giebel S. et al. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology 2019; 24 (01) 337-348
- 11 National Cancer Grid. National Cancer Grid Guidelines 2019: Adult Hematolymphoid Malignancies Management Guidelines. Accessed April 11, 2023 at: https://tmc.gov.in/ncg/docs/pdf/NCG_Guidelines_%202019/NCG%20Guidelines%20for%20Adult%20Hematolymphoid-2019.pdf
- 12 Ganesan P, Kayal S, How I. Treat adult acute lymphoblastic leukemia in India. Indian J Med Paediatr Oncol 2021; 42 (06) 584-594
- 13 Yadav V, Ganesan P, Veeramani R, Kumar V D. Philadelphia-like acute lymphoblastic leukemia: a systematic review. Clin Lymphoma Myeloma Leuk 2021; 21 (01) e57-e65
- 14 Svaton M, Skotnicova A, Reznickova L. et al. NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol. Blood 2023; 141 (05) 529-533
- 15 Döhner H, Wei AH, Appelbaum FR. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022; 140 (12) 1345-1377
- 16 Pollyea DA, Bixby D, Perl A. et al. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc Netw 2021; 19 (01) 16-27
- 17 El Achi H, Kanagal-Shamanna R. Biomarkers in acute myeloid leukemia: leveraging next generation sequencing data for optimal therapeutic strategies. Front Oncol 2021; 11: 748250
- 18 Slovak ML, Kopecky KJ, Cassileth PA. et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96 (13) 4075-4083
- 19 Hourigan CS. Achieving MRD negativity in AML: how important is this and how do we get there?. Hematology (Am Soc Hematol Educ Program) 2022; 2022 (01) 9-14
- 20 Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 2016; 34 (24) 2851-2857
- 21 Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol 2022; 97 (09) 1236-1256
- 22 Clark RE, Apperley JF, Copland M, Cicconi S. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood Adv 2021; 5 (04) 1102-1109
- 23 Guilhot F. Cytogenetics in CML: more important than you think. Blood 2016; 127 (22) 2661-2662
- 24 Ni J, Hong J, Zhang Z. et al. Marrow fibrosis is an independent predictor of hematological toxicity of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Leuk Lymphoma 2020; 61 (05) 1195-1200
- 25 Cross NCP, White HE, Evans PAS. et al. Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK. Br J Haematol 2018; 182 (06) 777-788
- 26 Shanmuganathan N, Pagani IS, Ross DM. et al. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood 2021; 137 (09) 1196-1207
- 27 Soverini S, Abruzzese E, Bocchia M. et al. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. J Hematol Oncol 2019; 12 (01) 131
- 28 Soverini S, Bernardi S, Galimberti S. Molecular testing in CML between old and new methods: are we at a turning point?. J Clin Med 2020; 9 (12) 3865
- 29 Burger JA. Treatment of chronic lymphocytic leukemia. N Engl J Med 2020; 383 (05) 460-473
- 30 Jain N, Keating M, Thompson P. et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial. JAMA Oncol 2021; 7 (08) 1213-1219
- 31 Catherwood MA, Wren D, Chiecchio L. et al. TP53 mutations identified using NGS comprise the overwhelming majority of TP53 disruptions in CLL: results from a multicentre study. Front Oncol 2022; 12: 909615
- 32 Crombie J, Davids MS. IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol 2017; 92 (12) 1393-1397
- 33 Alaggio R, Amador C, Anagnostopoulos I. et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022; 36 (07) 1720-1748
- 34 Friedberg JW. How I treat double-hit lymphoma. Blood 2017; 130 (05) 590-596
- 35 Susanibar-Adaniya S, Barta SK. 2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol 2021; 96 (05) 617-629
- 36 Swerdlow SH, Campo E, Pileri SA. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127 (20) 2375-2390
- 37 Di Napoli A, Remotti D, Agostinelli C. et al. A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era: selecting cases, matching clinical benefit : a position paper from the Italian Group of Haematopathology (G.I.E.). Virchows Arch 2019; 475 (04) 513-518
- 38 Alkan S, Cosar E, Ergin M, Hsi E. Detection of T-cell receptor-γ gene rearrangement in lymphoproliferative disorders by temperature gradient gel electrophoresis. Arch Pathol Lab Med 2001; 125 (02) 202-207
- 39 Palumbo A, Rajkumar SV, San Miguel JF. et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014; 32 (06) 587-600
- 40 Ding H, Xu J, Lin Z. et al. Minimal residual disease in multiple myeloma: current status. Biomark Res 2021; 9 (01) 75
- 41 Granell M, Calvo X, Garcia-Guiñón A. et al; GEMMAC (Grup per l'estudi del mieloma i l'amiloïdosi de Catalunya). Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica 2017; 102 (06) 1099-1104
- 42 Barbui T, Thiele J, Gisslinger H. et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 2018; 8 (02) 15
- 43 Grinfeld J, Nangalia J, Baxter EJ. et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med 2018; 379 (15) 1416-1430
- 44 Della Starza I, Chiaretti S, De Propris MS. et al. Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances. Front Oncol 2019; 9 (726): 726
- 45 Fürstenau M, De Silva N, Eichhorst B, Hallek M. Minimal residual disease assessment in CLL: ready for use in clinical routine?. HemaSphere 2019; 3 (05) e287
- 46 DiNardo CD, Jonas BA, Pullarkat V. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020; 383 (07) 617-629
- 47 Facon T, Kumar S, Plesner T. et al; MAIA Trial Investigators. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019; 380 (22) 2104-2115
- 48 Kantarjian H, Stein A, Gökbuget N. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017; 376 (09) 836-847
- 49 Khoury JD, Solary E, Abla O. et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022; 36 (07) 1703-1719
- 50 Ganesan P. Interim-response-adapted therapy in advanced Hodgkin's lymphoma: current status. Indian J Med Paediatr Oncol 2019; 40 (04) 566-569
- 51 Jain N, Lamb AV, O'Brien S. et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood 2016; 127 (15) 1863-1869
- 52 Ravandi F. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2019; 133 (02) 130-136
- 53 Alexander TB, Orgel E. Mixed phenotype acute leukemia: current approaches to diagnosis and treatment. Curr Oncol Rep 2021; 23 (02) 22
- 54 Heuser M, Freeman SD, Ossenkoppele GJ. et al. 2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2021; 138 (26) 2753-2767